BioVentrix Inc.
Minimally invasive and non-surgical treatments for HF
This article was originally published in Start Up
Executive Summary
The most prevalent kind of heart failure is caused by heart attack damage to the left ventricle, and the standard treatment is an open-heart procedure called surgical ventricular restoration. BioVentrix Inc. aims to replace SVR with a less invasive version of the procedure, using its Revivent Myocardial Anchoring System, designed to pull the damaged segments of the left ventricle together to reduce the burden on the non-damaged myocardium and improve its performance.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.